Securities code: 688767 securities abbreviation: Hangzhou Biotest Biotech Co.Ltd(688767) Announcement No.: 2022-001 Hangzhou Biotest Biotech Co.Ltd(688767)
Announcement of annual performance increase in 2021
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal liabilities for the authenticity, accuracy and integrity of its contents according to law.
1、 Performance forecast of the current period
(I) performance forecast period
From January 1, 2021 to December 31, 2021.
(II) performance forecast
1. According to the preliminary calculation of the financial department, the net profit attributable to the owner of the parent company in 2021 is expected to increase by 400 million yuan to 45 million yuan compared with the same period of the previous year (legally disclosed data), with a year-on-year increase (or decrease) of about XX% (or XX% to XX%).
2. Compared with the same period of last year (legally disclosed data), the net profit attributable to the owner of the parent company after deducting non recurring profits and losses will increase by XX million yuan (or XX million to XX million yuan), with a year-on-year increase of about XX% (or XX% to XX%).
(III) this performance forecast has not been audited by certified public accountants.
2、 Performance in the same period of last year
Net profit attributable to the owner of the parent company: XXXX million yuan.
Net profit attributable to the owner of the parent company after deducting non recurring profits and losses: RMB XXXX million.
3、 Main reasons for performance changes in the current period
During the reporting period, the COVID-19 epidemic continues to be repeated throughout the world. The company continued to fully support the global epidemic prevention and control. In the first half of 2021, the company’s New Coronavirus antigen detection kit achieved significant sales in Europe. In the second half of the year, the New Coronavirus antigen family self testing kit developed by the company was awarded the European Union CE. With the registration of TGA in Australia, under the influence of delta, Omicron and other variants of covid-19 virus, the number of covid-19 infection cases in Europe, Australia and other countries and regions continued to increase significantly, and the demand for covid-19 antigen detection reagent increased significantly, which directly led to the significant growth of the company’s overseas covid-19 detection reagent revenue. 4、 Risk tips
The company has no uncertain factors affecting the accuracy of the performance forecast, and the performance forecast has not been audited by certified public accountants.
5、 Other explanatory matters
The above forecast data are only preliminary accounting data. The specific and accurate financial data shall be subject to the audited annual report of 2021 officially disclosed by the company. Please pay attention to the investment risks.
It is hereby announced.
Hangzhou Biotest Biotech Co.Ltd(688767) board of directors January 21, 2022
